Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent


Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced a collaboration with Pradeep Mammen, MD, FACC, FAHA, founder and Medical Director of the Neuromuscular Cardiomyopathy Clinic at the University of Texas Southwestern (UT Southwestern) Medical Center as well as Co-Director of the National Institute of Health Sponsored UT Southwestern Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center. The mission of this center is to rapidly translate discoveries at the bench into therapies for Duchenne muscular dystrophy (DMD) in the clinic. The collaboration is designed to explore the potential of edasalonexent, a novel oral NF-kB inhibitor, to improve cardiac function in Duchenne and Becker muscular dystrophies.

https://www.duchennexchange.org/wp-content/uploads/2018/10/Catabasis-logo_RGB-high-res_9-2016.jpg